Nurix Therapeutics Stock Investor Sentiment

NRIX Stock  USD 15.45  0.45  3.00%   
Slightly above 68 percent of all Nurix Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Nurix Therapeutics suggests that a large number of traders are confidant. Nurix Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Nurix Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Nurix Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Nurix Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
58.4%
52.7%
51.5%
51.1%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Nurix Therapeutics Maximum Pain Price Across April 17th 2025 Option Contracts

Nurix Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Nurix Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Nurix Therapeutics' options.
Calls PricePuts Price
over three months ago at thelincolnianonline.com         
Nurix Therapeutics Now Covered by Analysts at Jefferies Financial Group
news
over three months ago at zacks.com         
Nurix Therapeutics, Inc. Reports Q3 Loss, Lags Revenue Estimates
zacks News
over three months ago at gurufocus.com         
Nurix Therapeutics Inc Q3 Earnings EPS of Beats Estimates, Revenue of 12. ...
Gurufocus Stories at Macroaxis
over three months ago at thelincolnianonline.com         
Nurix Therapeutics Sees Large Volume Increase Still a Buy?
news
over three months ago at finance.yahoo.com         
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the Americ...
Yahoo News
over three months ago at www.macroaxis.com         
Disposition of 300 shares by Christine Ring of Nurix Therapeutics at 22.81 subject to Rule 16b-3
Macroaxis News
over three months ago at finance.yahoo.com         
Nurix Therapeutics Announces Presentations atDiscovery on Target Conference
Yahoo News
over three months ago at news.google.com         
Nurix Therapeutics, Inc. Position Lessened by Ensign Peak Advisors Inc - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Fred Alger Management LLC Acquires New Shares in Nurix Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Renaissance Technologies LLC Purchases 144,700 Shares of Nurix Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
First Week of November 15th Options Trading For Nurix Therapeutics - Nasdaq
Google News at Macroaxis
over three months ago at gurufocus.com         
NRIX A Compelling Buy Scenario For Biopharmaceutical Investors
Gurufocus Stories at Macroaxis
over three months ago at simplywall.st         
Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.s Shares
Simply Wall St News at Macroaxis
over three months ago at finance.yahoo.com         
Nurix Therapeutics To Participate in UpcomingADC Radiopharmaceuticals Pharma Biotech Partnering Summ...
Yahoo News
over three months ago at globenewswire.com         
Nurix Therapeutics To Participate in UpcomingADC Radiopharmaceuticals Pharma Biotech Partnering Summ...
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Nurix Therapeutics that are available to investors today. That information is available publicly through Nurix media outlets and privately through word of mouth or via Nurix internal channels. However, regardless of the origin, that massive amount of Nurix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nurix Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nurix Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nurix Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nurix Therapeutics alpha.

Nurix Therapeutics Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.1512345678910Dec2025Feb -25-20-15-10-50
JavaScript chart by amCharts 3.21.15Nurix Therapeutics Nurix Therapeutics Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstroms Macroglobulinemia
12/19/2024
2
Disposition of 5760 shares by Christine Ring of Nurix Therapeutics at 19.4956 subject to Rule 16b-3
01/02/2025
3
Nurix Therapeutics Inc Reports Promising Clinical Results and Strategic Developments
01/28/2025
4
Disposition of 2000 shares by Van Houte Hans of Nurix Therapeutics subject to Rule 16b-3
01/30/2025
5
Disposition of 5537 shares by Christine Ring of Nurix Therapeutics at 1.86 subject to Rule 16b-3
01/31/2025
6
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
02/04/2025
7
Acquisition by Gwenn Hansen of 34300 shares of Nurix Therapeutics subject to Rule 16b-3
02/11/2025
8
Acquisition by Van Houte Hans of 34300 shares of Nurix Therapeutics subject to Rule 16b-3
02/13/2025
9
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
02/14/2025
10
ARK Investment Management LLC Sells 686,072 Shares of Nurix Therapeutics, Inc. - MarketBeat
02/26/2025

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.